NR3C1 and cancer: These findings were supported with a distinct pharmacological approach using a GR antagonist, mifepristone, which also prevented the increase in PAI-1 expression (Figure S4), again strongly suggesting the existence of direct GR-dependent regulation of PAI-1 expression in cancer cells.